| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| ViroLogic, Inc. |
| 270 East Grand Avenue, South San Francisco, CA 94080 * (650) 635-1100 |
| Business Description | The company is a biotechnology company developing and marketing innovative products to guide and improve treatment of viral diseases. |
| Offering Information Company has | |||
| Trading As | VLGC (NASNTL) | Industry | Service (SIC 8734) |
| Type of Stock Offered | Common Shares | Filing Date | 2/22/00 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 5/1/00 |
| Foreign Shares Offered | 0 | Filing Range | $7.00 - $8.00 |
| Company Shares | 5,000,000 | Offer Price | $7.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.490 |
| Gross Proceeds | $35,000,000 | Selling | $0.250 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 19,690,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| CIBC World Markets | Lead Manager | (212) 667-7400 |
| ING Baring Furman Selz | Co-manager | (212) 309-8200 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | |||
| Revenues | - | 0.000 | 0.000 | 0.102 | 1.069 | - | - |
| Income from Oper. | - | -1.377 | -3.316 | -8.158 | -15.964 | - | - |
| Net Income | - | -1.274 | -3.137 | -8.054 | -15.958 | - | - |
| E.P.S | - | -0.740 | -1.210 | -1.710 | -3.340 | - | - |
| Revenue Growth (%) | - | - | - | 948.039 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -13.39 | - | - | ||||
| Cash Flow - Inv. | -3.95 | - | - | ||||
| Cash Flow - Fin. | 9.98 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 9.78 | Current Assets | 4.31 | Current Ratio | 1.14 |
| Total Liab. | 5.08 | Current Liab. | 3.78 | Debt Ratio | 51.95% |
| Total Equity | 4.70 | Working Cap. | 0.52 | Debt to Equity Ratio | 1.08 |
| Cash | 2.21 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for sales and marketing, capital expenditures including the expansion of our clinical laboratory capabilities, research and development, and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | McDermott, Will & Emery |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Biotech Growth S. A. | 25.60 | |
| Zesiger Capital Group | 18.20 | |
| Capital Management Services, Inc. | 6.50 | |
| Note: represents ownership of 5% or more prior to the offering. | ||